Wall Street expects a year-over-year increase in earnings on higher revenues when TG Therapeutics (TGTX) reports results for the quarter ended December 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the ...

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Thursday, February 26, 2026, at 8:30 AM ET to discuss results for the fourth quarter and full year 2025 and to provide a business outlook for 2026. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics E ...

During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient treatment Overall safety profile of BRIUMVI remained consistent over 5 years of continuous treatment, with no new safety signals emerging with prolonged treatment NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the publication of long term/five-year data from the ongoing open-label extension (OLE) of the Phase 3 ULTIMAT ...

Core Insights - Generative AI is viewed as a transformative technology by Amazon's CEO Andy Jassy, indicating its potential to significantly enhance customer experiences across the company [1] - Elon Musk predicts that by 2040, humanoid robots could create a market worth $250 trillion, representing a major shift in the global economy driven by AI innovation [2][3] - Major firms like PwC and McKinsey acknowledge the multi-trillion-dollar potential of AI, suggesting a broad consensus on its economic impact [3] Company and Industry Analysis - A breakthrough in AI technology is redefining work, learning, and creativity, leading to increased interest from hedge funds and top investors [4] - There is speculation about an under-owned company that may play a crucial role in the AI revolution, with its technology posing a threat to competitors [4][6] - Prominent figures in technology and investment, including Bill Gates and Warren Buffett, recognize AI as a significant advancement with the potential for substantial social benefits [8] - The article suggests that investors may soon regret not owning shares in a specific AI company that is positioned to capitalize on this technological wave [9]

Core Insights - TG Therapeutics, Inc. has launched a new initiative in collaboration with actress Christina Applegate to raise awareness about multiple sclerosis (MS) and facilitate open conversations among those affected by the disease [3][4][7] Group 1: Campaign Overview - The campaign debuted during Super Bowl LX and introduced a new platform, www.NextInMS.com, aimed at creating a space for honest discussions among individuals living with MS [1][3] - Christina Applegate, who has been living with MS for five years, will lead this national disease-awareness initiative [4][5] - The platform will feature exclusive content, including Applegate's personal experiences and insights on navigating life with MS, as well as educational resources from MS experts [5][8] Group 2: Company Commitment - TG Therapeutics emphasizes its commitment to advancing innovation in MS treatment, which includes developing novel therapies and supporting resources for patients [7][9] - The collaboration with Applegate is seen as a way to resonate with the MS community and promote open dialogue about the challenges and realities of living with the disease [6][7]

Core Viewpoint - TG Therapeutics Inc. is recognized as one of the best revenue growth stocks to consider for investment, with analysts maintaining positive ratings despite some adjustments in price targets [1][3]. Group 1: Analyst Ratings and Price Targets - JPMorgan analyst Brian Cheng reduced the price target for TG Therapeutics from $49 to $46 while keeping an Overweight rating on the shares [1]. - H.C. Wainwright analyst Emily Bodnar assigned a Buy rating, highlighting the company's strong commercial momentum and expected clinical catalysts in 2026 [3]. - TD Cowen analyst Tara Bancroft reiterated a Buy rating and set a price target of $50 for TG Therapeutics [3]. Group 2: Clinical Developments - TG Therapeutics presented trial results for its Briumvi treatment for relapsing multiple sclerosis at a medical forum in San Diego on February 6 [3]. - The anticipated clinical catalysts include results for consolidated IV dosing and a self-administered subcutaneous formulation for Briumvi, which could enhance its market share against competitors [3].

Core Insights - TG Therapeutics presented data on BRIUMVI® (ublituximab-xiiy) at the ACTRIMS annual forum, focusing on its clinical applications and real-world study results [1][2]. Company Overview - TG Therapeutics is a biopharmaceutical company dedicated to developing treatments for B-cell diseases, with BRIUMVI approved for treating adult patients with relapsing forms of multiple sclerosis (RMS) [29]. Clinical Studies - The ENABLE study evaluates real-world infusion experiences of patients with RMS on BRIUMVI, showcasing the company's commitment to advancing clinical understanding [2]. - The ULTIMATE I & II trials are Phase 3 studies involving 1,094 patients across 10 countries, comparing BRIUMVI to teriflunomide over 96 weeks [4]. Product Information - BRIUMVI is a monoclonal antibody targeting CD20-expressing B-cells, designed to enhance B-cell depletion efficiency through glycoengineering [5][6]. - It is indicated for various forms of RMS, including clinically isolated syndrome and active secondary progressive disease [7]. Safety and Efficacy Data - In clinical trials, BRIUMVI showed a 56% overall infection rate compared to 54% for teriflunomide, with serious infections at 5% versus 3% [10]. - Infusion reactions occurred in 48% of patients receiving BRIUMVI, with serious reactions in 0.6% [8]. Market Context - Approximately 1 million people in the U.S. are living with MS, with 85% initially diagnosed with relapsing-remitting MS [28].

Core Viewpoint - The article aims to provide informational content regarding investment opportunities and risks, emphasizing the importance of independent research and verification by readers [2][3]. Group 1: Company Analysis - The article does not provide specific details about any particular company or its financial performance, focusing instead on general investment advice [2][3]. Group 2: Industry Insights - There are no specific insights or analyses related to any industry mentioned in the article, as it primarily serves as a general informational piece [2][3].

Core Viewpoint - The article aims to provide informational content regarding investment opportunities and risks, emphasizing the importance of independent research and verification by readers [2][3]. Group 1: Company Analysis - The article does not provide specific details about any particular company or its financial performance, focusing instead on general investment advice [2][3]. Group 2: Industry Insights - There are no specific insights or analyses related to any industry mentioned in the article, as it primarily serves as a general informational piece [2][3].

Core Insights - TG Therapeutics is focused on developing treatments for B-cell diseases, with its flagship product BRIUMVI targeting relapsing multiple sclerosis (RMS) [1] Financial Performance - Goldman Sachs updated its rating for TG Therapeutics to Neutral, maintaining a hold recommendation, with the stock price at $29.54 and a raised price target from $37 to $39 [2][6] - TG Therapeutics projects FY25 revenue to reach approximately $616 million, an 87% increase from $329 million in FY24, and anticipates FY26 revenue between $875 million and $900 million [3][6] - BRIUMVI is expected to contribute around $594 million in product revenue for FY25, with FY26 projections ranging from $825 million to $850 million [4][6] Market Position - Despite a 7.7% decline in shares over the past year, TG Therapeutics remains optimistic about long-term revenue growth driven by BRIUMVI's commercial performance and market share capture [5]